News, 7 August 2025:  Rejuve.Bio, the BioAI company pioneering a neural-symbolic AI‑driven co-scientist platform aimed at accelerating drug discovery for extending human healthspan and targeting age‑associated diseases will sponsor the Aging Research & Drug Discovery Meeting (ARDD 2025), the world's largest biopharmaceutical industry conference on aging research. 

The paper introduces DAC’s “6 x 5 strategy” — six foundational pillars over five years — to advance early detection, timely care, data-driven systems, and equitable innovation. A new Pan-African Task Force has been launched to implement the plan and promote brain health as an engine of inclusive development and economic resilience.

Targeted drug delivery to tumors is crucial for effective and safe treatment of cancer. In a recent breakthrough, researchers from Okayama University have developed a pH-responsive nanomaterial using graphene oxide and polyglycerol for cancer drug delivery. The surface of the developed nanomaterial changes its charge in an acidic tumor environment and enables uptake of drugs by cancer cells while avoiding immune clearance. This innovative approach opens doors to precision-driven and more efficient cancer therapies.

Over 25 years of studying individuals aged 80 and older — dubbed “SuperAgers” — Northwestern University scientists have seen some notable lifestyle and personality differences between SuperAgers and those aging typically — such as being social and gregarious — but “it’s really what we’ve found in their brains that’s been so earth-shattering for us,” the corresponding author said.